Aequus Pharmaceuticals Inc. (AQS.V)
CAD 0.01
(0.0%)
CAD 0.01
(0.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 4.89 Million CAD | 817.94% |
| 2022 | 533.1 Thousand CAD | 352.29% |
| 2021 | -211.3 Thousand CAD | -134.94% |
| 2020 | 604.73 Thousand CAD | -65.1% |
| 2019 | 1.73 Million CAD | 568.44% |
| 2018 | -369.89 Thousand CAD | 68.24% |
| 2017 | -1.16 Million CAD | -146.07% |
| 2016 | -473.24 Thousand CAD | 59.34% |
| 2015 | -1.16 Million CAD | 67.46% |
| 2014 | -3.57 Million CAD | -1047.16% |
| 2013 | -311.73 Thousand CAD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | 5.51 Million CAD | 13.27% |
| 2024 Q1 | 5.43 Million CAD | 10.97% |
| 2023 Q3 | 3.97 Million CAD | 20.13% |
| 2023 FY | 4.89 Million CAD | 817.94% |
| 2023 Q4 | 4.89 Million CAD | 23.09% |
| 2023 Q1 | 2.81 Million CAD | 428.46% |
| 2023 Q2 | 3.3 Million CAD | 17.46% |
| 2022 Q1 | -30.48 Thousand CAD | 85.57% |
| 2022 Q3 | 2.06 Million CAD | 157.52% |
| 2022 Q2 | 802.87 Thousand CAD | 2734.02% |
| 2022 FY | 533.1 Thousand CAD | 352.29% |
| 2022 Q4 | 533.1 Thousand CAD | -74.22% |
| 2021 Q1 | -1.24 Million CAD | -306.38% |
| 2021 FY | -211.3 Thousand CAD | -134.94% |
| 2021 Q4 | -211.3 Thousand CAD | 71.19% |
| 2021 Q3 | -733.55 Thousand CAD | 51.47% |
| 2021 Q2 | -1.51 Million CAD | -21.12% |
| 2020 Q2 | 2.08 Million CAD | 6.3% |
| 2020 Q3 | 88.85 Thousand CAD | -95.73% |
| 2020 Q4 | 604.73 Thousand CAD | 580.62% |
| 2020 FY | 604.73 Thousand CAD | -65.1% |
| 2020 Q1 | 1.95 Million CAD | 12.94% |
| 2019 Q3 | 987.24 Thousand CAD | 74.14% |
| 2019 Q1 | 116.7 Thousand CAD | 131.55% |
| 2019 Q2 | 566.93 Thousand CAD | 385.78% |
| 2019 Q4 | 1.73 Million CAD | 75.51% |
| 2019 FY | 1.73 Million CAD | 568.44% |
| 2018 Q4 | -369.89 Thousand CAD | 62.38% |
| 2018 Q2 | -450.52 Thousand CAD | 46.51% |
| 2018 Q1 | -842.29 Thousand CAD | 27.67% |
| 2018 FY | -369.89 Thousand CAD | 68.24% |
| 2018 Q3 | -983.11 Thousand CAD | -118.22% |
| 2017 Q4 | -1.16 Million CAD | 37.4% |
| 2017 Q1 | -4.05 Million CAD | -757.78% |
| 2017 FY | -1.16 Million CAD | -146.07% |
| 2017 Q2 | -3.09 Million CAD | 23.85% |
| 2017 Q3 | -1.86 Million CAD | 39.82% |
| 2016 Q1 | -767.67 Thousand CAD | 34.04% |
| 2016 Q2 | -328.42 Thousand CAD | 57.22% |
| 2016 FY | -473.24 Thousand CAD | 59.34% |
| 2016 Q4 | -473.24 Thousand CAD | 60.31% |
| 2016 Q3 | -1.19 Million CAD | -263.02% |
| 2015 Q1 | -2.26 Million CAD | 36.53% |
| 2015 Q3 | -385.08 Thousand CAD | 71.26% |
| 2015 FY | -1.16 Million CAD | 67.46% |
| 2015 Q4 | -1.16 Million CAD | -202.23% |
| 2015 Q2 | -1.33 Million CAD | 40.97% |
| 2014 Q4 | -3.57 Million CAD | -2707.16% |
| 2014 Q3 | -127.39 Thousand CAD | 0.0% |
| 2014 Q1 | 311.73 Thousand CAD | 200.0% |
| 2014 FY | -3.57 Million CAD | -1047.16% |
| 2013 FY | -311.73 Thousand CAD | 0.0% |
| 2013 Q4 | -311.73 Thousand CAD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| CanadaBis Capital Inc. | 4.08 Million CAD | -19.82% |
| Decibel Cannabis Company Inc. | 37.48 Million CAD | 86.945% |
| Delivra Health Brands Inc. | -2.17 Million CAD | 325.199% |
| Entourage Health Corp. | 150.32 Million CAD | 96.745% |
| Lifeist Wellness Inc. | -188.12 Thousand CAD | 2701.183% |
| Cannara Biotech Inc. | 41.51 Million CAD | 88.212% |
| Medicure Inc. | -5.82 Million CAD | 184.01% |
| PharmaCielo Ltd. | 18.24 Million CAD | 73.181% |
| Rubicon Organics Inc. | 475.37 Thousand CAD | -929.421% |
| BioSyent Inc. | -3.68 Million CAD | 232.798% |
| Voyageur Pharmaceuticals Ltd. | 37.91 Thousand CAD | -12806.71% |